Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001193125-25-291688
Filing Date
2025-11-21
Accepted
2025-11-21 18:25:28
Documents
1
Period of Report
2025-11-20

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3182
  Complete submission text file 0001193125-25-291688.txt   4642
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Issuer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O AKERO THERAPEUTICS 601 GATEWAY BLVD #350 SOUTH SAN FRANCISCO CA 94080
Business Address
Cheng Andrew (Reporting) CIK: 0001778307 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38944 | Film No.: 251509250